id.DRIVE is a privately funded not-for-profit open public-private partnership that facilitates the conduct of observational and low interventional studies on infectious diseases and related vaccines, preventive measures, therapeutics and diagnostics. These studies support  public health responses globally and address pharmaceutical companies’ regulatory obligations. This multi-stakeholder partnership brings together public institutions, small and medium sized enterprises (SMEs) and pharmaceutical companies. As an open partnership, id.DRIVE welcomes new partners and study contributors (sites) anytime.

id.DRIVE was launched in 2024 as the successor of COVIDRIVE, a public-private partnership that was set up in 2021 amidst the COVID-19 pandemic to perform COVID-19 Vaccine Effectiveness studies. COVIDRIVE rooted in from the European Commission Innovative Medicines Initiative (IMI)-funded DRIVE consortium for Influenza Vaccine Effectiveness evaluation in Europe (2017-2022). id.DRIVE expands the scope of COVIDRIVE beyond COVID-19 and runs several studies across different respiratory infectious diseases, with a focus on surveillance and vaccine effectiveness.